TY - JOUR
T1 - International interlaboratory digital PCR study demonstrating high reproducibility for the measurement of a rare sequence variant
AU - Whale, Alexandra S.
AU - Devonshire, Alison S.
AU - Karlin-Neumann, George
AU - Regan, Jack
AU - Javier, Leanne
AU - Cowen, Simon
AU - Fernandez-Gonzalez, Ana
AU - Jones, Gerwyn M.
AU - Redshaw, Nicholas
AU - Beck, Julia
AU - Berger, Andreas W.
AU - Combaret, Valerie
AU - Kjersgaard, Nina Dahl
AU - Davis, Lisa
AU - Fina, Frederic
AU - Forshew, Tim
AU - Andersen, Rikke Fredslund
AU - Galbiati, Silvia
AU - Hernandez, Alvaro Gonzalez
AU - Haynes, Charles A.
AU - Janku, Filip
AU - Lacave, Roger
AU - Lee, Justin
AU - Mistry, Vilas
AU - Pender, Alexandra
AU - Pradines, Anne
AU - Proudhon, Charlotte
AU - Saal, Lao H.
AU - Stieglitz, Elliot
AU - Ulrich, Bryan
AU - Foy, Carole A.
AU - Parkes, Helen
AU - Tzonev, Svilen
AU - Huggett, Jim F.
PY - 2017
Y1 - 2017
N2 - This study tested the claim that digital PCR (dPCR) can offer highly reproducible quantitative measurements in disparate laboratories. Twenty-one laboratories measured four blinded samples containing different quantities of a KRAS fragment encoding G12D, an important genetic marker for guiding therapy of certain cancers. This marker is challenging to quantify reproducibly using quantitative PCR (qPCR) or next generation sequencing (NGS) due to the presence of competing wild type sequences and the need for calibration. Using dPCR, 18 laboratories were able to quantify the G12D marker within 12% of each other in all samples. Three laboratories appeared to measure consistently outlying results; however, proper application of a follow-up analysis recommendation rectified their data. Our findings show that dPCR has demonstrable reproducibility across a large number of laboratories without calibration. This could enable the reproducible application of molecular stratification to guide therapy and, potentially, for molecular diagnostics.
AB - This study tested the claim that digital PCR (dPCR) can offer highly reproducible quantitative measurements in disparate laboratories. Twenty-one laboratories measured four blinded samples containing different quantities of a KRAS fragment encoding G12D, an important genetic marker for guiding therapy of certain cancers. This marker is challenging to quantify reproducibly using quantitative PCR (qPCR) or next generation sequencing (NGS) due to the presence of competing wild type sequences and the need for calibration. Using dPCR, 18 laboratories were able to quantify the G12D marker within 12% of each other in all samples. Three laboratories appeared to measure consistently outlying results; however, proper application of a follow-up analysis recommendation rectified their data. Our findings show that dPCR has demonstrable reproducibility across a large number of laboratories without calibration. This could enable the reproducible application of molecular stratification to guide therapy and, potentially, for molecular diagnostics.
U2 - 10.1021/acs.analchem.6b03980
DO - 10.1021/acs.analchem.6b03980
M3 - Journal article
C2 - 27935690
AN - SCOPUS:85026741973
SN - 0003-2700
VL - 89
SP - 1724
EP - 1733
JO - Analytical Chemistry
JF - Analytical Chemistry
IS - 3
ER -